Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease

Ann Hematol. 2018 Jan;97(1):185-187. doi: 10.1007/s00277-017-3114-7. Epub 2017 Aug 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cytarabine / administration & dosage
  • Cytarabine / therapeutic use*
  • Drug Therapy, Combination
  • Erdheim-Chester Disease / drug therapy*
  • Erdheim-Chester Disease / genetics
  • Erdheim-Chester Disease / pathology
  • Frontal Lobe / diagnostic imaging
  • Frontal Lobe / pathology*
  • Gyrus Cinguli / diagnostic imaging
  • Gyrus Cinguli / pathology*
  • Histiocytes / pathology
  • Humans
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography
  • Proto-Oncogene Proteins B-raf / genetics*
  • Recurrence

Substances

  • Interferon-alpha
  • Cytarabine
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf